1 US penny stock I’m avoiding like the plague

This medical penny stock’s trying to capture a $100bn market opportunity after recently receiving FDA approval. But personally, I’m not touching it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny stocks offer some of the most explosive growth potential in the stock market. That’s why these tiny enterprises are so popular. However, they also come paired with tremendous risk, even if the business offers a product or service that seems game-changing.

Outset Medical (NASDAQ:OM) seems to be a perfect example of this. With a market capitalisation of just $63m, the room for growth seems to be quite impressive. Even more so given the firm’s goal of simplifying and reducing the cost of dialysis with its Tablo system.

Yet, despite all this potential, the Outset Medical share price has been seemingly heading in just one direction – down — and I’m definitely not interested.

Should you invest £1,000 in Unilever right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Unilever made the list?

See the 6 stocks

A failure of management

It’s hard to argue that the Tablo system is a phenomenal piece of medical technology. Typically, patients suffering from kidney failure have to go to hospitals or clinics to get treatment. However, with Tablo, the entire process can be done from the comfort of home without the need for a medical professional.

That certainly sounds like an exciting investment opportunity, especially since the global dialysis market size is estimated to be worth over $100bn. Yet in the last few years, this opportunity has turned into a bit of a nightmare. In fact, since the start of 2022, Outset Medical’s share price has collapsed by 97%, placing it firmly within penny stock territory.

A few things went wrong here. A new study found that GLP weight-loss drugs, like Ozempic, could be used as a viable alternative to dialysis for patients suffering from kidney failure. This revelation understandably spooked investors in dialysis companies like Outset Medical and Abbott Laboratories.

However since 2022, Abbott’s only down around 18%. That’s not great. But it’s massively better than what Outset has delivered.

Outset’s collapse seems to be tied to a complete loss of faith in management. Leadership failed to file the proper paperwork with the FDA on time, creating regulatory delays. A few months later this issue was resolved, and a new partnership with the US’s largest private dialysis provider seemed to have put the firm back on track.

Yet a few months after that, disaster struck once again with disappointing results and the announcement of a complete revamp to the group’s go-to-market strategy that could take “several quarters to fully implement and realise fully”.

In other words, Outset appears to be taking one step forward, two steps back. And investors’ patience has disappeared.

Hope for a comeback?

Looking at this business, it’s not all bad news. The threat of GLP drugs may be a bit overblown. There’s still a lot of research that needs to be performed, and clinical studies could take years to measure long-term impacts. In the meantime, demand for dialysis machines, especially portable ones like Outset’s Tablo Cart, isn’t likely to disappear.

Management switching tactics is frustrating. But changing course may be necessary. After all, if the current plan isn’t delivering results, there’s no point continuing with it.

Right now, the penny stock’s trading at a forward price-to-sales ratio of 0.6. That’s pretty cheap, indicating that the bar has been set very low, opening the door to an explosive comeback if management can get things back on track. However, personally, I’ll believe it when I see it at this stage.

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »